MedTrace Logo

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

NCT07253688 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2025-12-10

No results posted yet for this study

Summary

This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.

Conditions

  • Staphylococcus Aureus Endocarditis
  • Prosthetic Valve Endocarditis

Interventions

DRUG

Rifampin

Patients will receive rifampin 900mg a day in 2-3 divided doses

OTHER

No rifampin

Subjects will be assigned to not receive adjunctive rifampin

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of Melbourne

    collaborator OTHER

  • The Peter Doherty Institute for Infection and Immunity

    collaborator OTHER

  • Todd C. Lee MD MPH FIDSA

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-10
Primary Completion
2029-12-31
Completion
2030-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07253688 on ClinicalTrials.gov